Trasylol


Also found in: Dictionary.

Trasylol

 [tras´-lol]
trademark for a preparation of aprotinin, an antihemorrhagic agent.

Trasylol

(trăs′ə-lŏl)
A trademark for the drug aprotinin.

Trasylol

[tras′ilol]
a trademark for a preparation of aprotinin, an antihemorrhagic agent.

aprotinin

A bovine polypeptide and protease inhibitor with antifibrinolytic activity that derives from basic pancreatic trypsin inhibitor (BPTI), which was added to fibrinogen in “fibrin glue”, theoretically enhancing the persistence of the fibrin clot.

It was pulled from the international market in 2007, given the concern that aprotinin increased the risk of complications and death during surgery. In 2012 the European Medicines Agency concluded that the benefits outweighed the risks, and recommended the suspension be lifted.

Trasylol

A brand name for APROTININ.
References in periodicals archive ?
has notified the FDA that the company will begin removing the remaining Trasylol stock from the US.
Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the US market after a long-awaited study found it raised the risk of death compared to two alternatives, US regulators said.
Medicos alemanes, austriacos, italianos y norteamericanos extrajeron tejidos de los muslos o del pulmon de personas con lesiones graves sin su consentimiento y sin que lo supieran, para determinar como actuaba el Trasylol en los tejidos y se adulteraron las tasas de mortalidad por el uso de este medicamento.
Aprotinin is marketed as Trasylol by Bayer Pharmaceuticals in Levekusen, Germany.
The Food and Drug Administration is warning physicians that the blood-loss prevention drug Trasylol (aprotinin injection) has been linked to higher risks of kidney problems, heart attacks, and strokes in patients who undergo coronary artery bypass graft surgery.
It is currently marketed under the name of Trasylol by Bayer Corp.
Most notably, she has served as national trial counsel in major multidistrict litigation involving pharmaceutical product liability, including the Vioxx, Trasylol and YAZ/Yasmin matters.
Blood was collected, using a Vacutainer[R] system, directly into 4 tubes of each of the tube-types studied: lithium heparin with 2000 U/tube of trasylol (L), citrate (C), EDTA (E), serum clot-activator (S), and serum separator (SST) tubes (BD Vacutainer[R] Blood Collection Tubes).
has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.
Bayer AG apologized to US regulators for withholding information about the risks of its drug Trasylol last year, urging that the treatment used in heart bypass surgery be permitted to remain on the market.
Trasylol was designed by Bayer to reduce bleeding during open-heart surgery.
The drug, aprotinin, sold under the brand name Trasylol, is widely used to prevent or reduce blood loss during the surgery.